edaravone has been researched along with Cognitive Decline in 10 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study investigated the effects of edaravone, a potent free radical scavenger, on intermittent hypoxia (IH)-induced oxidative damage and cognition impairment in a young rat model of IH." | 7.96 | Edaravone Improves Intermittent Hypoxia-Induced Cognitive Impairment and Hippocampal Damage in Rats. ( Duan, Y; Guo, T; Li, L; Li, Y; Ling, J; Liu, W; Wang, X; Yu, Q; Yuan, X, 2020) |
| " This study investigated the effects of edaravone, a potent free radical scavenger, on intermittent hypoxia (IH)-induced oxidative damage and cognition impairment in a young rat model of IH." | 3.96 | Edaravone Improves Intermittent Hypoxia-Induced Cognitive Impairment and Hippocampal Damage in Rats. ( Duan, Y; Guo, T; Li, L; Li, Y; Ling, J; Liu, W; Wang, X; Yu, Q; Yuan, X, 2020) |
| "Edaravone is a mitochondrially targeted drug with a suggested capability to modify the course of diverse neurological diseases." | 1.91 | Experimental Treatment with Edaravone in a Mouse Model of Spinocerebellar Ataxia 1. ( Benediktova, S; Cendelin, J; Jedlicka, J; Jelinkova, D; Kapl, S; Kuncova, J; Purkartova, Z; Sucha, M; Tichanek, F; Tuma, J, 2023) |
| "Edaravone is a new type of oxygen free radical scavenger and able to attenuate various brain damage including hypoxic-ischemic brain damage (HIBD)." | 1.48 | Edaravone attenuates neuronal apoptosis in hypoxic-ischemic brain damage rat model via suppression of TRAIL signaling pathway. ( Fu, R; Huang, Y; Lei, J; Li, C; Li, H; Luo, S; Mo, Z; Zhang, L, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 5 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sucha, M | 1 |
| Benediktova, S | 1 |
| Tichanek, F | 1 |
| Jedlicka, J | 1 |
| Kapl, S | 1 |
| Jelinkova, D | 1 |
| Purkartova, Z | 1 |
| Tuma, J | 1 |
| Kuncova, J | 1 |
| Cendelin, J | 1 |
| Li, L | 2 |
| He, G | 1 |
| Shi, M | 1 |
| Zhu, J | 1 |
| Cheng, Y | 1 |
| Chen, Y | 2 |
| Chen, J | 1 |
| Xue, Q | 1 |
| Zhou, Y | 1 |
| Wu, X | 1 |
| Ye, L | 1 |
| Bai, Y | 1 |
| Zhang, H | 2 |
| Xuan, Z | 1 |
| Feng, Y | 1 |
| Zhang, P | 1 |
| Yan, Y | 1 |
| Zhu, B | 1 |
| Cui, W | 1 |
| Ling, J | 1 |
| Yu, Q | 1 |
| Li, Y | 1 |
| Yuan, X | 1 |
| Wang, X | 1 |
| Liu, W | 1 |
| Guo, T | 1 |
| Duan, Y | 1 |
| Fan, SR | 1 |
| Ren, TT | 1 |
| Yun, MY | 1 |
| Lan, R | 1 |
| Qin, XY | 1 |
| Li, C | 1 |
| Mo, Z | 1 |
| Lei, J | 1 |
| Li, H | 1 |
| Fu, R | 1 |
| Huang, Y | 1 |
| Luo, S | 1 |
| Zhang, L | 2 |
| Guo, Y | 1 |
| Wang, H | 1 |
| Zhao, L | 1 |
| Ma, Z | 1 |
| Li, T | 1 |
| Liu, J | 1 |
| Sun, M | 1 |
| Jian, Y | 1 |
| Yao, L | 1 |
| Du, Y | 1 |
| Zhang, G | 1 |
| Yoshino, H | 1 |
| Wang, P | 1 |
| Cao, J | 1 |
| Liu, N | 1 |
| Ma, L | 1 |
| Zhou, X | 1 |
| Wang, Y | 1 |
| Reeta, KH | 1 |
| Singh, D | 1 |
| Gupta, YK | 1 |
1 review available for edaravone and Cognitive Decline
| Article | Year |
|---|---|
Edaravone for the treatment of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Cognitive Dysfunction; Edaravone; Free Radical Scavengers; Humans; Ne | 2019 |
9 other studies available for edaravone and Cognitive Decline
| Article | Year |
|---|---|
Experimental Treatment with Edaravone in a Mouse Model of Spinocerebellar Ataxia 1.
Topics: Animals; Bayes Theorem; Cerebellum; Cognitive Dysfunction; Disease Models, Animal; Edaravone; Mice; | 2023 |
Edaravone dexborneol ameliorates cognitive impairment by regulating the NF-κB pathway through AHR and promoting microglial polarization towards the M2 phenotype in mice with bilateral carotid artery stenosis (BCAS).
Topics: Animals; Carotid Stenosis; Cognitive Dysfunction; Edaravone; Mice; Microglia; NF-kappa B; Receptors, | 2023 |
Edaravone at high concentrations attenuates cognitive dysfunctions induced by abdominal surgery under general anesthesia in aged mice.
Topics: Abdominal Wall; Aging; Anesthesia, General; Animals; Cognitive Dysfunction; Dose-Response Relationsh | 2020 |
Edaravone Improves Intermittent Hypoxia-Induced Cognitive Impairment and Hippocampal Damage in Rats.
Topics: Animals; Cognitive Dysfunction; Cyclic AMP; Cyclic AMP Response Element-Binding Protein; Cyclic AMP- | 2020 |
Edaravone attenuates cadmium-induced toxicity by inhibiting oxidative stress and inflammation in ICR mice.
Topics: Animals; Brain; Cadmium; Cell Line, Tumor; Cell Survival; Cognitive Dysfunction; Dose-Response Relat | 2021 |
Edaravone attenuates neuronal apoptosis in hypoxic-ischemic brain damage rat model via suppression of TRAIL signaling pathway.
Topics: Animals; Animals, Newborn; Apoptosis; Cognitive Dysfunction; Disease Models, Animal; Edaravone; Gene | 2018 |
Edaravone reduces Aβ-induced oxidative damage in SH-SY5Y cells by activating the Nrf2/ARE signaling pathway.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidant Response Elements; Apoptosis; Cell Li | 2019 |
Protective Effects of Edaravone in Adult Rats with Surgery and Lipopolysaccharide Administration-Induced Cognitive Function Impairment.
Topics: Animals; Antipyrine; Brain; Cognitive Dysfunction; Cytokines; Disease Models, Animal; Edaravone; Fre | 2016 |
Edaravone attenuates intracerebroventricular streptozotocin-induced cognitive impairment in rats.
Topics: Animals; Antipyrine; Cerebral Cortex; Cholinesterases; Cognitive Dysfunction; Cytokines; Edaravone; | 2017 |